Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus SIMVASTATIN.
Head-to-head clinical analysis: BAYCOL versus SIMVASTATIN.
BAYCOL vs SIMVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, increases LDL receptor expression, and lowers plasma LDL cholesterol.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
10-40 mg orally once daily in the evening; maximum 80 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Clinical Note
moderateSimvastatin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Prednisolone
"The serum concentration of Prednisolone can be increased when it is combined with Simvastatin."
Clinical Note
moderateSimvastatin + Resveratrol
The terminal elimination half-life of simvastatin is approximately 2-3 hours, but for the active metabolite (simvastatin acid) it is about 1.9 hours; clinical lipid-lowering effects persist longer due to sustained HMG-CoA reductase inhibition.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Primarily hepatic metabolism, with approximately 13% excreted in urine as metabolites and 60% in feces via biliary elimination; less than 0.5% of the active form is excreted unchanged in urine.
Category C
Category D/X
Statin
Statin
"The serum concentration of Resveratrol can be increased when it is combined with Simvastatin."